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ACVRIB-positive cells
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Abstract
Background: Esophageal squamous cell carcinoma (ESCC) is a global public health issue, as it is the eighth most
common cancer worldwide. The mechanisms behind ESCC invasion and progression are still poorly understood,
and warrant further investigation into these processes and their drivers. In recent years, the ligand Activin A has
been implicated as a player in the progression of a number of cancers. The objective of this study was to
investigate the role of Activin A signaling in ESCC.
Methods: To investigate the role Activin A plays in ESCC biology, tissue microarrays containing 200 cores from
120 ESCC patients were analyzed upon immunofluorescence staining. We utilized three-dimensional organotypic
reconstruct cultures of dysplastic and esophageal squamous tumor cells lines, in the context of fibroblast-secreted
Activin A, to identify the effects of Activin A on cell invasion and determine protein expression and localization
in epithelial and stromal compartments by immunofluorescence. To identify the functional consequences of
stromal-derived Activin A on angiogenesis, we performed endothelial tube formation assays.
Results: Analysis of ESCC patient samples indicated that patients with high stromal Activin A expression had low
epithelial ACVRIB, the Activin type I receptor. We found that overexpression of stromal-derived Activin A inhibited
invasion of esophageal dysplastic squamous cells, ECdnT, and TE-2 ESCC cells, both positive for ACVRIB. This
inhibition was accompanied by a decrease in expression of the extracellular matrix (ECM) protein fibronectin
and podoplanin, which is often expressed at the leading edge during invasion. Endothelial tube formation
was disrupted in the presence of conditioned media from fibroblasts overexpressing Activin A. Interestingly,
ACVRIB-negative TE-11 cells did not show the prior observed effects in the context of Activin A overexpression,
indicating a dependence on the presence of ACVRIB.
Conclusions: We describe the first observation of an inhibitory role for Activin A in ESCC progression that is
dependent on the expression of ACVRIB.
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Background
Esophageal cancer is the eighth most prevalent cancer
and sixth most common cause of cancer-related deaths
globally [1, 2]. The different subtypes are esophageal
adenocarcinoma (EAC) and esophageal squamous cell
carcinoma (ESCC). Though the prevalence of EAC has
now surpassed that of ESCC in North America and
Europe, ESCC remains the dominant subtype globally
(~80 %), with the highest incidence and mortality occur-
ring in developing countries in Asia [2–4]. ESCC poses a
great public health challenge, as little progress has been
made in improving diagnosis and outcomes for patients.
Approximately 80 % of ESCC is diagnosed in late stage
and has only a 15 % 5-year survival rate; these statistics
have remained stagnant over the last 20 years [1–3].
Though the list of targeted therapies is constantly
growing, therapeutic resistance and recurrence persist to
occur [2–5]. To address this problem, an examination of
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new diagnostic and prognostic indicators, as well as the
mechanisms underlying progression, is needed to provide
further insight into new methods to combat ESCC.
Activin A, a homodimer of inhibin βA subunits, has
been indicated as a key player in ovarian, prostate and
breast cancers [6, 7]. A member of the TGFβ superfamily,
Activin A, upon binding an Activin type II (ActRII/B) and
type I (ACVRI/B) receptor, subsequently activates the
Smad cascade thereby driving transcription of target genes
(reviewed in [8]). Activin A was initially discovered as a
gonadotroph, where it acts as a potent inducer of cell
cycle arrest [9, 10]. In vivo knock-down of inhibin βA in
mice leads to incomplete development [11] and defects in
squamous tissue wound healing [12]. Although previously
linked to carcinogenesis [13], the mechanism and precise
contribution of Activin A to initiation and progression
remains to be elucidated. Studies in gastric cancer have
shown Activin A to be a potent inhibitor of angiogenesis
and inducer of apoptosis [14, 15]; however, similar to
TGFβ, Activin A can act as a tumor promoter or suppres-
sor in different contexts. In breast cancer, some reports
have indicated that Activin A can induce cell growth and
epithelial-mesenchymal transition [16, 17], whereas other
studies have demonstrated that Activin A treatment
induces cell cycle arrest and inhibits growth [10, 18].
This “dual role” phenomenon has also been observed in
prostate [19] and lung [20, 21] cancers.
In the esophagus, clinical and experimental evidence
has indicated that Activin A promotes cancer progression.
Clinical studies have correlated increased Activin A
expression with tumor aggressiveness, differentiation
status [22], and poor patient prognosis [23]. Several
explanations have been suggested to explain the mecha-
nisms induced by Activin A. In ESCC, one such pro-
posal for Activin A contribution to tumor progression
is through the induction of N-cadherin, with subsequent
loss of E-cadherin, a feature that has been associated with
increased tumor aggressiveness [24]. Additional evidence
has suggested that Activin A can upregulate MMP-7
expression, which has been correlated with gastric and
colorectal cancers [25] via the transcription factor AP-1,
a non-canonical pathway [26].
Taken together, contrary to its characterization as an
inhibitor of angiogenesis and growth suppressor, Acti-
vin A overexpression contributes to ESCC indicating
that during cancer progression this signaling pathway
switches function from an anti-tumorigenic to pro-
tumorigenic regulation. Of particular importance is the
contribution of the microenvironment in this context,
which we investigate here. Activin A has been shown to
not only exert functional effects on tumor cells, but also
on stromal cells located within the microenvironment,
where Activin A can induce a “wound healing” phenotype
(reviewed in [27]).
To address the contrasting roles of Activin A, a growth
inhibitor known to be highly expressed in several cancers,
we aimed to determine the source of Activin A (stromal
versus epithelial-secreted) and to mimic stromal over-
expression in an organotypic reconstruct culture system. In
this study, we show that, in a dysplastic esophageal micro-
environment, fibroblast-secreted Activin A, as one source
of stromal Activin A, suppresses cell invasion through the
inhibition of epithelial cell proliferation and the regulation
extracellular matrix components. We further observed that
esophageal TE-2 tumor cells respond to fibroblast-derived
Activin A with inhibition of cell invasion similar to the
dysplastic cells, yet this effect was not observed in the
Activin receptor IB (ACVRIB)-negative ESCC cell line
TE-11. We conclude that during cancer progression, in
concordance with upregulated stromal Activin A expres-
sion, ACVRIB is frequently downregulated in ESCC cells,
allowing an escape from the inhibitory effects of Activin A
as a novel mechanism of esophageal tumorigenesis.
Methods
Cell lines and cell culture
Fetal esophageal fibroblasts were cultured in Dulbecco’s
Modified Eagle Medium (DMEM) (Gibco, Grand Island,
NY) supplemented with 10 % fetal bovine serum (FBS)
(Atlanta Biologicals, Norcross, GA) and 1 % penicillin
and streptomycin (P/S) (Gibco) [28]. Primary esophageal
keratinocytes expressing dominant-negative mutants of
E-cadherin and TβRII (ECdnT), established as previously
described [29], were cultured in keratinocyte serum-free
media (KSFM) supplemented with 40 μg/mL bovine pitu-
itary extract, 1 ng/mL epidermal growth factor (EGF), and
1 % P/S (Gibco). The ESCC cell lines TE-2 and TE-11
were grown in RPMI and DMEM (Gibco), respectively,
and supplemented with 10 % FBS and 1 % P/S [30]. The
endothelial cell line HMEC-1 were cultured in MCDB131
(Gibco) supplemented with 10 % FBS, 10 ng/ml EGF,
1 μg/ml hydrocortisone (Sigma), and 1 % P/S [31].
Retrovirus infection
Overexpression of Activin A was performed using a
retroviral construct containing cDNA for INHBA, the
sequence that encodes the inhibin βA subunit, as previ-
ously described [32]. The vector backbone pBABE-zeo
was purchased from AddGene (plasmid #1766 [33]) and
inhibin βA cDNA was inserted at the multiple cloning site.
Virus was generated using Phoenix-Ampho HEK293T cells
(ATCC CRL-3213). Fibroblasts (Fibro-ActA) were then
transduced and selected using Zeocin (Life Technologies)
at a concentration of 800 μg/ml. Fibroblasts transduced
with an empty pBABE-zeo vector (Empty) and untrans-
fected parent fibroblasts (Parent) were used as controls.
Activin A overexpression was validated by ELISA.
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Cell contraction assay
Cell contraction assay was performed according to the
manufacturers’ protocol (Cell Biolabs, Inc., San Diego, CA).
3-butanedione monoxime (BDM) was used as a control.
ELISA
Capture ELISAs for Activin A were purchased from
R&D Systems (Minneapolis, MN) and performed using
conditioned media according to the manufacturers’
instructions.
Organotypic culture
Organotypic reconstruct cultures were performed as
previously described [34]. Briefly, parental, empty, or
fibroblasts with Activin A overexpression were seeded
into a 3D matrix (75,000 cells/well) containing collagen
I and Matrigel (BD Biosciences, Franklin Lakes, NJ)
and allowed to incubate for 7 days at 37 °C. Following
incubation, ECdnT, TE-2, or TE-11 cells were seeded
on top of the fibroblast matrix (500,000 cells/well).
Cultures were then allowed to incubate an additional
10 days. Treatments were added to the cultures begin-
ning two hours following epithelial cell seeding and
refreshed every 2 days. A neutralizing antibody against
Activin A (nAb; R&D Systems) and A83-01, a chemical
inhibitor of TGFβ/Activin A/BMP type I receptors
(ACVRIB/TβRI/ALK7) (Tocris, Bristol, UK), were used
for treatment.
Staining
Immunofluorescence of FFPE sections
At time of harvest, organotypic cultures were fixed in
10 % formalin and embedded in paraffin. Cultures were
cut to 5 μm sections, deparaffinized, and heated for
12 min in 1XTE buffer in a pressure cooker to perform
antigen retrieval. Sections were blocked with 1XPBS
containing 5 % bovine serum albumin (1XPBST + BSA;
Sigma-Aldrich) for one hour at room temperature. The
sections were incubated with primary antibody diluted
in 1XPBS + BSA overnight at 4 °C. The following day,
sections were washed three times with 1XPBS, and
incubated with a secondary antibody with a conjugated
fluorophore (anti-rabbit Texas Red 1:200, Vector
Laboratories, Burlingame, CA; anti-mouse DyLight
Alexa488 1:200, Vector Laboratories; anti-rat Alexa594
1:200, Life Technologies), diluted in 1XPBS + BSA, for
1–2 h at room temperature. Sections were washed
three times and mounted using ProLong Gold anti-fade
with DAPI (Life Technologies). Sections were imaged
on a Zeiss microscope, using Axiocam and AxioVision
software (Carl Zeiss Microscopy, Thornwood, NY).
Antibodies used for immunofluorescence are listed in
Table 1.
Endothelial tube formation assay
Growth factor-reduced Matrigel (Corning) was added to
each well of a 96-well plate and allowed to solidify at
37 °C for approximately 30 min. HMEC-1 cells, in the
appropriate conditioned media treatment, were seeded
at 15,000 cells/well, in triplicate, to the Matrigel-containing
wells and incubated for 18 h at 37 °C. Following incuba-
tion, bright field images of each well were taken and
analyzed using Angiogenesis Analyzer for ImageJ [35].
This software allows network organization analysis of a
skeleton or tree, extremities or nodes and junctions in a
binary image (http://image.bio.methods.free.fr/ImageJ/
?Angiogenesis-Analyzer-for-ImageJ&lang=en&artpage=
3-7#outil_sommaire_3). Statistical analysis was performed
by one-way ANOVA in GraphPad.
ESCC tissue microarray
Microarrays were purchased from US Biomax (Rockville,
MD). Following immunofluorescence staining, cores were
quantified using the “Measure Stained Area Fluorescence”
algorithm as part of the Leica Microsystems Tissue IA
version 4.0.6 program (Buffalo Grove, IL). Fluorescence
area was measured in μm2. Antibodies used for im-
munofluorescence are listed in Table 1.
Statistical analysis
Experimental results were analyzed using Student’s t-test
or one-way ANOVA and expressed as the mean +/-
standard deviation. Statistical analysis of the in vitro
experiments was performed in Prism 6.0 (GraphPad,
San Diego, CA). ESCC microarrays were analyzed using
linear generalized estimating equations (GEE) or Kruskal-
Wallis tests. For matched samples, Wilcoxon signed rank
Table 1 Antibodies used for immunofluorescence
Antibody Dilution Application Vendor
Podoplanin 1:500 Immunofluorescence eBioscience
Vimentin 1:1000 Immunofluorescence Sigma
N-cadherin 1:500 Immunofluorescence BD Bioscience
Fibronectin 1:1000 Immunofluorescence BD Bioscience
E-cadherin 1:1000 Immunofluorescence BD Bioscience
Vimentin 1:50 Immunofluorescence Cell Signal Technology
Laminin 5γ2 1:200 Immunofluorescence Santa Cruz Biotechnology
Ki67 1:200 Immunofluorescence Cell Signal Technology
Collagen IV 1:200 Immunofluorescence Cell Signal Technology
αSMA 1:200 Immunofluorescence Sigma
COL4A2 1:100 TMA Chondrex
INHBA 1:200 TMA ProteinTech
CD68 1:20 TMA R&D Systems
ACVRIB 1:200 TMA Abcam
Keratin 14 1:50 TMA Abcam
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tests were used. Results are expressed as the mean +/-
standard deviation. Statistical analysis of the microarrays
was performed using SPSS (IBM, Armonk, NY).
Results
Epithelial ACVRIB expression levels are dependent upon
expression of stromal Activin A in ESCC
It has been well established that Activin A expression in
normal physiology is low with increased expression in
invasive cancer [23, 36–38]. We first aimed to determine
the localization and expression level of Activin A in
ESCC tissues. Using commercially purchased tissue
microarrays, we stained 200 esophageal tissues (cancer
adjacent, squamous cell carcinoma, and lymph node
[LN] metastases) from 120 patients for Activin A and
ACVRIB, the primary type I receptor involved in Activin
A signaling (Fig. 1a). Additional staining for keratin 14
(K14) to determine squamous cells, vimentin (Vim) to
identify mesenchymal cells, and collagen as well as CD68,
a glycoprotein expressed in monocytes, were used as
controls. These markers allowed us to compartmentalize
the localization of Activin A and ACVRIB localization
Fig. 1 Epithelial ACVRIB expression in ESCC patient samples is dependent upon the expression of Activin A. a Representative immunofluorescence
staining of microarray samples (whole section image shown of tumor tissues Stage I-IV and lymph node [LN]) for INHBA/Activin A, ACVRIB, K14, and
vimentin (Vim). b Using a linear generalized estimating equation (GEE), a significant interaction was found between total Activin A expression
and epithelial ACVRIB as a predictor of stage. Though epithelial ACVRIB expression was not a predictor of stage alone, we found that stromal
INHBA/Activin A and epithelial ACVRIB expression showed a significant interaction. Analysis of immunofluorescence was performed on the whole
tissue section. (TMA = 200 cores) c Graphical illustration of the relationship between epithelial expression of ACVRIB and stromal expression of
ACVRIIB, measured by intensity in μm2, in the TMA samples. Each dot represents a single patient sample. d Western blot of ACVRIB and ACVRIIB
of the TE series of ESCC cell lines. β-actin was used as a loading control
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to epithelial/tumor or stroma. Data are quantified in
Additional file 1: Figure S1. Using Kruskal-Wallis tests
and generalized estimating equations (GEE), we found
that Activin A expression alone was not associated with
tumor stage in this set of tumor tissues, similarly ACVRIB
expression alone varied between stage and was not a
predictor of tumor stage (data not shown). However, we
identified that after controlling for epithelial ACVRIB
expression, Activin A expression in the stroma was,
indeed, a significant predictor of stage, when analyzed by
multivariable GEE analysis (Fig. 1b). Therefore, we deter-
mined that with increasing stromal Activin A expression,
epithelial ACVRIB expression decreases within this pa-
tient data set, thereby, promoting a more aggressive ESCC
phenotype as illustrated by increased stage. This relation-
ship is illustrated in Fig. 1c. We next examined 9 com-
monly utilized ESCC cell lines for protein expression of
ACVRIB and ACVRIIB, the primary Activin A type II re-
ceptor (Fig. 1d). ACVRIB expression was low in 3 out of 9
cell lines and barely detectable in 4 out of 9, indicating
decreased expression in 7 out of 9 ESCC cell lines. On the
contrary, ACVRIIB was downregulated in only one cell
line, TE-5. To reconcile the high Activin A levels in the
context of decreased ACVRIB expression and the func-
tional consequences, we next grew dysplastic and TE-2
and TE-11 cancer cell lines in organotypic cultures.
Fibroblast-secreted Activin A inhibits cell invasion of
dysplastic esophageal cells and regulates extracellular
matrix protein expression
Fibroblasts play a substantial role in inflammation,
wound healing, and extracellular matrix (ECM) deposition
[39, 40]. In the context of cancer, fibroblasts are recruited
by cancer cells via epithelial-mesenchymal crosstalk to re-
arrange the ECM to create a ‘reactive’ stroma, which pro-
vides an environment conducive to cell invasion [41, 42].
Microenvironment-derived Activin A has been implicated
as part of the reactive stroma phenotype [43, 44]. Consid-
ering elevated levels of Activin A are found in the stroma
despite the characteristic function of Activin A as an
inducer of growth arrest, we first aimed to investigate the
role of microenvironment-derived Activin A in a three-
dimensional organotypic reconstruct (OTC) model in the
presence of dysplastic esophageal keratinocytes (ECdnT)
[29]. As normal esophageal fibroblasts secrete low to
negligible levels of Activin A ([34] and data not shown), we
retroviral transduced fibroblasts with INHBA to achieve
Activin A overexpression levels similar to those observed in
cancer-associated fibroblasts [34, 43]. Upon embedding
Activin A overexpressing fibroblasts (Fibro-ActA) in the
organotypic culture matrix, we validated overexpression
and secretion of Activin A by ELISA (Additional file 2:
Figure S2a). Fibro-ActA secreted significantly more Activin
A than the tested epithelial cells, ensuring that the majority
of Activin A in OTC would be derived from the fibroblasts.
To confirm that Activin A overexpression was maintained
during the course of each OTC (17 days), we collected
media every 2 days and measured Activin A concentrations
by ELISA (Additional file 2: Figure S2b-d). Parent and
empty vector fibroblasts were used as controls.
ECdnT cells showed collective cell invasion and kera-
tin pearl formation characteristic of an invasive ESCC
when cultured with control parent and empty vector
fibroblasts (Fig. 2a, b). When cultured with Fibro-ActA,
ECdnT cell invasion was suppressed (Fig. 2c). Immuno-
fluorescence staining was performed with anti-E-cadherin
(E-cad) antibody to identify the epithelial compartment.
An examination of fibroblast protein expression by
immunofluorescence showed that vimentin (Vim), a mes-
enchymal marker, andαSMA and podoplanin (PDPN),
markers of fibroblast differentiation and activation, were
downregulated in Fibro-ActA cultures (Fig. 2d-i). We also
observed substantial downregulation of the ECM protein
fibronectin (FN) (Fig. 2j-l). Interestingly, the ability of
Fibro-ActA to interact with and contract the ECM was
not altered until the epithelial cells were seeded
(Additional file 2: Figure S2e, f ), indicating the necessity
of epithelial-mesenchymal crosstalk to modify contractil-
ity. Epithelial cell proliferation, measured by Ki67 staining,
did not change between conditions (Fig. 2m-o, Additional
file 3: Figure S3a). Interestingly, in all conditions, epithelial
cells deposited laminin 5γ2, a squamous epithelium base-
ment membrane marker [45], and collagen IV, a major
basement membrane component (Fig. 2p-r) [46]. Collagen
IV localization to the basement membrane, however, was
slightly reduced in Fibro-ActA cultures (Fig. 2s-x, arrows).
These results support the role of Activin A as an invasion
suppressor and indicate Activin A-dependent regulation
of ECM-associated proteins.
Inhibition of Activin A signaling during dysplasia restores
extracellular matrix protein expression
To demonstrate Activin A-dependence and specificity of
epithelial invasion inhibition and the expression of several
ECM proteins, we used two separate approaches for
Activin A inhibition: a neutralizing antibody specific for
the Activin A ligand (nAb) and A83-01, a chemical inhibi-
tor of TGFβ/Activin A/BMP type I receptors (ACVRIB/
TβRI/ALK7) [47]. We have previously shown the ability of
nAb and A83-01 to neutralize Activin A signaling in this
model system [34, 48]. Treatment with nAb increased cell
invasion in dysplastic empty vector control cells, yet could
not overcome the inhibition of cell invasion in the context
of Fibro-ActA cultures (Fig. 3a-d). Similarly, A83-01
treatment, while increasing cell invasion in the ECdnT
cultures with empty vector control, could not restore cell
invasion in the Fibro-ActA cultures (Fig. 3e, f ). When
we examined ECM protein expression in these cultures
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by immunofluorescence, treatment with nAb could re-
store expression of fibrillar fibronectin in Fibro-ActA,
similar to that observed in empty vector untreated
cultures, yet A83-01 prevented their restoration. We
also observed restoration of podoplanin (Fig. 3g-r). This
indicates the necessity of Activin A signaling to induce
expression of these proteins. Laminin 5γ2 was upregu-
lated in the Fibro-ActA cultures treated with both nAb
and A83-01, the only tested marker to do so (Fig. 3s-x).
This result indicates that one potential mechanism of
regulating laminin 5γ2 expression is through the Activin
A-ACVRIB axis. Epithelial cell proliferation, measured by
Ki67, was inhibited with the addition of A83-01 to all
cultures, but was unaltered in the presence of nAb
(Fig. 3y-d’). Interestingly, when we examined the basal epi-
thelial layer of the Fibro-ActA cultures treated with nAb,
we also found collagen IV deposition at the basement mem-
brane (Fig. 3e’-h’). This was not observed in cultures treated
with A83-01 (Fig. 3i’-j’; higher magnification Fig. 3k’-p’).
We, therefore, conclude that the blocking of Activin
A-receptor binding is necessary to inhibit the observed
ECM alterations, yet not sufficient to induce cell invasion.
Fig. 2 Overexpression of Activin A in the dysplastic esophageal microenvironment inhibits extracellular matrix protein reorganization. a-c
Hematoxylin and eosin staining of parent, empty, and Fibro-ActA organotypic cultures. d-f Three-dimensional organotypic Fibro-ActA cultures
exhibit no alterations in epithelial ECdnT E-cadherin (E-cad) expression, however vimentin (Vim) is downregulated in the fibroblasts, as examined
by immunofluorescence. g-i αSMA expression was substantially downregulated in the fibroblasts, while podoplanin (PDPN) expression was
downregulated in both epithelial cells and fibroblasts. The asterisks(*) in the parental and empty vector cultures denote co-localization of αSMA
and PDPN, a common characteristic of cancer-associated fibroblasts. j-l Fibronectin (FN) deposition was decreased in Fibro-ActA cultures compared to
parent and empty vector controls. m-r Ki67, a marker of proliferation, and laminin 5γ2, a marker of basal cell differentiation, was unchanged between
conditions. s-u Collagen IV deposition, a primary component of basement membrane deposition, was decreased in Fibro-ActA compared to control.
v-x Collagen IV staining, higher magnification of boxed region in s-u. Arrows indicate the collagen IV basement membrane, laid by the epithelial cells.
(Short scale bar = 20 μm; long scale bar = 5 μm) (n = 4)
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Stromal Activin A inhibits TE-2 cell invasion in
three-dimensional culture
As we observed that fibroblast-derived overexpression of
Activin A inhibited cell invasion in premalignant cells,
we aimed to investigate if Activin A has a similar effect
on cancer cells. We cultured the ESCC cell line TE-2
with Fibro-ActA. TE-2 cells express the Activin A recep-
tor complex components, ACVRIIB and ACVRIB (Fig. 1d).
Similar to the dysplastic model, TE-2 cells were unable to
invade into the stromal layer when cultured with Fibro-
ActA, compared to controls (Fig. 4a-c). As in the ECdnT
cultures (Fig. 2), E-cadherin marks the epithelial layer and
vimentin labels the fibroblasts in the stromal compart-
ment (Fig. 4d-f). Interestingly, we observed co-localization
of αSMA and podoplanin in the control fibroblasts
(Fig. 4g-h, asterisks), not seen in the Fibro-ActA fibro-
blasts, suggesting differentiation to a myofibroblast lineage
in the invasive tumor cultures [49].
Unlike the ECdnT cultures, we observed differences
in Ki67 staining between TE-2 Fibro-ActA and control
cultures indicating significantly decreased proliferation
compared to controls, as indicated by Ki67 staining
(Fig. 4m-o, Additional file 3: Figure S3b). Similarly to
our observations with in the premalignant ECdnT model,
laminin 5γ2 expression was unchanged between condi-
tions (Fig. 4p-r). Collagen IV deposition in the basal layer
was downregulated in Fibro-ActA (Fig. 3s-x).
Overall, these observations suggest that the TE-2 ESCC
cell line responds to the overexpression of Activin A by
the fibroblasts in a similar manner to the dysplastic,
premalignant ECdnT model. This prompted us to
analyze the effects of Fibro-ActA on the TE-11 ESCC
cell lines, which we determined has low ACVRIB
protein expression (Fig. 1d).
Cell invasion and regulation of the ECM proteins requires
intact Activin A signaling
Cancer cells have the ability to adapt in response to en-
vironmental factors. One such mechanism of adaptation
is cancer cell clonal expansion, where one cancer cell
with a particular advantage is able to survive and expand
[50]. Downregulation or loss of components of the TGFβ
signaling cascade, such as TβRII, has been noted in sev-
eral cancers and associated with increased aggressiveness
Fig. 3 Inhibition of the Activin A ligand, but not the receptor, restores extracellular matrix protein expression. (a-f) Hematoxylin and eosin
staining shows that ECdnT cells didn’t invade in any of the Fibro-ActA cultures, however invasion was increased in empty vector cultures treated
with an Activin A neutralizing antibody (nAb) or A83-01. (g-l) Epithelial cell podoplanin (PDPN) expression was restored to control levels in Fibro-ActA
cultures following treatment with nAb. (m-r) Treatment of Fibro-ActA cultures with nAb partially restored stromal fibrillar fibronectin (FN) expression
(asterisks) to untreated empty vector control levels. This effect was not observed following treatment with A83-01. (s-x) Laminin 5γ2 expression was
increased in Fibro-ActA cultures treated with nAb and A83-01. (y-d’) Ki67 staining remained relatively unchanged between conditions. (e’-j’) Collagen
IV deposition at the basement membrane was restored to the expression level of the control upon treatment of Fibro-ActA with nAb. This deposition
was not observed in Fibro-ActA cultures treated with A83-01. (k’-p’) Collagen IV staining, higher magnification of boxed region in e’-j’. Arrows indicate
the collagen IV basement membrane, laid by the epithelial cells. (Short scale bar = 20 μm; long scale bar = 5 μm) (n = 2)
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[29, 51, 52]. Similar observations have been made re-
garding the members of the Activin A signaling cascade
[53]. Given the observation that Activin A levels are
high in the tumor setting and Activin A acts as an inva-
sion suppressor for TE-2 cells, we used a ACVRIB-
negative cell line, which has disrupted Activin A signal-
ing due to the lost receptor complex component, to
provide validation and mechanistic insight to the pa-
tient sample observations (Fig. 1). As ACVRIB is the
primary signaling kinase for the Activin A cascade, as
discussed above, we chose the cell line, TE-11, which
had low ACVRIB expression (Fig. 1d) to evaluate the
response of ACVRIB-negative cells to fibroblast-derived
Activin A. TE-11 cells invaded into the stroma, shown
by H&E staining, in both Fibro-ActA and control
cultures (Fig. 5a-c). By immunofluorescence, we exam-
ined the same epithelial, stromal, and ECM markers
used in the previous experiments (Figs. 2, 3 and 4). As
expected, in the TE-11 cultures, Activin A secretion by
the fibroblasts did not alter the overall expression of
vimentin, αSMA, podoplanin, and fibronectin (Fig. 5d-l).
Similarly to the TE-2 cultures, co-localization of αSMA
Fig. 4 Overexpression of Activin A shows similar extracellular matrix protein regulation in ACVRIB-expressing ESCC. a-c Hematoxylin and eosin
staining of parent, empty, and Fibro-ActA organotypic cultures, cultured with TE-2 ESCC cells. d-f Three-dimensional organotypic Fibro-ActA cultures
exhibit no alterations in epithelial ECdnT E-cadherin (E-cad) expression, however vimentin (Vim) is downregulated in the fibroblasts, as examined by
immunofluorescence. g-i αSMA and podoplanin (PDPN) expression was significantly downregulated in the fibroblasts and epithelial cells, respectively.
The asterisks(*) in the parental and empty vector cultures denote co-localization. j-l Fibronectin (FN) deposition was decreased in Fibro-ActA cultures
compared to parent and empty vector controls. m-o Ki67 staining was decreased in epithelial TE-2 cells cultured with Fibro-ActA, compared to parent
and empty vector cultures (quantification in Additional file 3: Figure S3). p-r Laminin 5γ2, a marker of basal cell differentiation, was unchanged between
conditions. s-u Collagen IV deposition, a primary component of basement membrane deposition, was decreased in Fibro-ActA compared to control.
v-x Collagen IV staining, higher magnification of boxed region in s-u. Arrows indicate the collagen IV basement membrane, laid by the epithelial cells.
(Short scale bar = 20 μm; long scale bar = 5 μm) (n = 2)
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and podoplanin was observed, however this was noted
in all cultures, including Fibro-ActA (Fig. 5g-i, aster-
isks). Ki67 and laminin 5γ2 expression was unchanged
between conditions (Fig. 5m-r). Deposition of collagen
IV, a common characteristic of cancer cells, [54] was
increased overall in TE-11 (Fig. 5s-x) [53]. In a related
study analyzing Activin A signaling in head-and-neck
squamous cell carcinoma (HNSCC), we observed
similar alterations of ECM proteins induced by Activin A
stimulation, which could no longer be deteted upon
utilizing knockout of ACVRIB in the HNSCC lines
(data not shown).
Taken together, we show that in contrast to the
dysplastic ECdnT cells and the TE-2 ESCC cell line,
fibroblast-secreted Activin A could not suppress TE-11
cell invasion nor were ECM components altered,
indicating the necessity of intact Activin A signaling to
mediate these effects. In the absence of ACVRIB, we
presume the tumor cells can escape Activin A-
meditated regulation with reciprocal consequences on
the ECM itself. This would explain the observation of
increased tumor stage in the human tissue set for
which stromal Activin A was high in tumors with low
ACVRIB expression.
Fig. 5 ACVRIB-negative ESCC shows epithelial alterations, however extracellular matrix protein expression remains unaltered. a-c Hematoxylin and
eosin staining of parent, empty, and Fibro-ActA organotypic cultures, cultured with TE-11 ESCC cells. Fibro-ActA cultures show increased keratin
deposition in the epithelial layer, compared to parent and empty vector controls. d-f Three-dimensional organotypic Fibro-ActA cultures exhibit
no alterations in epithelial E-cadherin (E-cad) or stromal vimentin (Vim) expression, as examined by immunofluorescence. g-i αSMA and podoplanin
(PDPN) expression was unchanged between conditions. Co-localization of the markers is denoted by asterisks(*). j-l Fibronectin (FN) deposition
and (m-o) Ki67 and (p-r) laminin5γ2 expression was not different between control (parent and empty) and Fibro-ActA. s-u Collagen IV deposition,
a primary component of basement membrane deposition, was decreased in Fibro-ActA compared to control. v-x Collagen IV staining, higher
magnification of boxed region in s-u. Arrows indicate the collagen IV basement membrane, laid by the epithelial cells. (Short scale bar = 20 μm;
long scale bar = 5 μm) (n = 2)
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Angiogenesis assessed by endothelial tube formation
is significantly inhibited following treatment with
conditioned media from Activin A overexpression cultures
Because matrix metalloproteases are known to be regulated
by TGFβ signaling pathways and have long been implicated
as necessities for epithelial cell invasion, we performed
gelatin zymography to examine total and active MMP-2
and MMP-9 expression. We found that expression of pro-
and cleaved MMP-2 were reduced in Fibro-ActA cultures
from ECdnT and TE-2 cells, yet their expression in TE-11
was not affected by fibroblast overexpression of Activin A
throughout the 17-day culture (Fig. 6a). Overall, MMP-9
expression and activity remained largely unchanged in the
different culture conditions, aside from an increase in ac-
tive MMP-9 in the TE-2 cells at the end of the culture (day
17) in the presence of Fibro-ActA. These results suggest
that, even in the presence of MMPs, which promote epithe-
lial cell invasion, Activin A is able to suppress this effect.
As MMPs, particularly MMP-2 and MMP-9, are neces-
sary for tumor angiogenesis (reviewed in [55]) and Activin
A has been characterized as a potent inhibitor of this
process [14, 56], we next examined the effect of Activin A
overexpressing cultures on endothelial tube formation.
We found that treatment of HMEC-1 endothelial cells
with conditioned media from dysplastic ECdnT cultured
with Fibro-ActA showed reduced tube formation, com-
pared to parent and empty vector control conditioned
media (Fig. 6b). This effect was also observed when using
TE-2 conditioned media from Fibro-ActA (Fig. 6b). Quan-
titative analysis of the assay images showed that HMEC-1
cells treated with Fibro-ActA conditioned media from
ECdnT and TE-2 cultures formed significantly less ex-
tremities, nodes, junctions, and branches, compared to
parent and empty vector control (Fig. 6c-j). These results
indicate that overexpression of Activin A, and its crosstalk
with the epithelial cell compartment in this context,
Fig. 6 Fibro-ActA conditioned media from three-dimensional organotypic cultures inhibits in vitro angiogenesis. a Gelatin zymography of conditioned
media collected from 3D-organotypic cultures at day 7 (fibroblasts alone), day 9 (media collection following the addition of epithelial cells), and day 17
(final collection). Arrows indicate the locations of pro- and cleaved MMP-2 and MMP-9. b Representative images of endothelial tube formation assays
using HMEC-1 cells. HMEC-1 endothelial cells cultured with day 9 conditioned media from ECdnT/Fibro-ActA and TE-2/Fibro-ActA cultures had
less overall tube formation, compared to parent and empty vector controls. This effect was not observed upon treatment with TE-11/Fibro-ActA
conditioned media. Quantification of endothelial extremities, nodes, junctions, and branches for the assays with ECdnT (c-f), TE-2 (g-j), and TE-11
(k-n) conditioned media shown in (b)
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results in the inhibition vessel formation, ultimately lead-
ing to suppression of tumor cell expansion. Conditioned
media from TE-11 cells cultured with Fibro-ActA,
however, failed to reduce tube formation and only a
significant reduction of nodes was observed (Fig. 6b, k-n).
Interestingly, treatment of HMEC-1 cells with recombin-
ant protein (TGFβ, Activin A, or the Activin A antagonist
Follistatin) or A83-01 were equally effective at inducing
tube formation (Additional file 4: Figure S4a-e). These re-
sults indicate that Activin A alone may not directly inhibit
angiogenesis, however it may regulate the expression of
several anti-angiogenic proteins to control this process
through epithelial-mesenchymal crosstalk.
Discussion
It has been well documented that TGFβ receptors,
which are closely related to Activin receptors, are down-
regulated as a means to evade growth suppression. In
colorectal cancer, aside from loss of Smad4, TβRI and
TβRII are commonly downregulated or lost [57]. Similar
observations have been made in laryngeal [58] and
gastric cancers (reviewed in [59]). The downregulation
of these receptors occurs concurrently with TGFβ upreg-
ulation [57]. As there are significant similarities between
these two pathways, the analogous observations made
between the TGFβ pathway, as shown in the literature,
and the Activin A pathway, demonstrated here, are not
surprising. ACVR2 mutations have been described to at-
tenuate Activin A signaling in prostate cancer [60] and
microsatellite unstable colon cancer [61]. The mutations
identified are similar to the well-characterized frameshift
mutations in TGFBR2 [62]. Inactivation of ACVRIB so
far has only been identified in pancreatic cancer as a
consequence of a somatic mutation [63], and homolo-
gous deletion is associated with an aggressive phenotype
in pancreatic cancer [64]. Based on the 120 esophageal
squamous tumor tissues we analyzed in this study, we
found that ACVRIB can also be lost in ESCC. Further-
more, while ACVRIB loss has not been described to
contribute to esophageal cancer, the overexpression of
Activin A has been identified previously to be associated
with enhanced matrix metalloprotease expression [26]
and ESCC aggressiveness [65], partially through upregu-
lated of N-cadherin [24]. We have additionally addressed
the loss of ACVRIB in the context of head and heck
squamous cell carcinoma and have observed results
similar to the data presented here (data not shown).
In our study we found not only that Activin A is
increased, but also that its location to the stroma is of
importance to the function. When overexpressed in the
tumor, Activin A confers differential effects. Some
cancers, such as lung and head and neck squamous cell
carcinoma, develop insensitivity to the growth inhibi-
tory effects of Activin A, one of the hallmarks of cancer
[66–69]. In prior studies, we have described that treat-
ment of premalignant cultures recombinant Activin A
induces esophageal cell invasion [34]. In this context,
however, signaling is not directional, as both epithelial
and stromal compartment are exposed to the recom-
binant Activin A. In the current study, we mimic the
stromal source of Activin A, which we observed in the
patient tissues. The fibroblast-secreted Activin A
therefore contrasts stimulation of the whole culture
with recombinant protein Activin A, showing inhibition
of esophageal cell invasion. This inhibition is a conse-
quence of intact Activin A signaling; however, loss of
ACVRIB allows esophageal cancer cells, such as TE-11
cells, to escape Activin A-dependent regulation.
Though the results of our study provide significant
insight into the role of Activin A signaling in cancer
progression, limitations remain. The three-dimensional
organotypic reconstruct culture system is an efficient
way to examine cellular crosstalk in vitro, however it is
a simplified environment and does not account for
additional components of the microenvironment, such
as endothelial cells or leukocytes. Activin A may be
secreted by, and signal within, a variety of cell types,
including those listed. In our study, we used fibroblasts
as a source of stromal Activin A, therefore accounting
for Activin A expression alone, but not effects within
the assorted cell types. The integration of different cell
types into this system will provide further into the sys-
temic effects of Activin A during cancer progression.
We aimed to focus on angiogenesis as one example of
the complex microenvironment, and to identify the
functional consequences of fibroblast-Activin A over-
expression using the endothelial tube formation assay.
Activin A has been consistently shown to function as a
potent anti-angiogenic factor, contrary to reports
indicating its oncogenic role. Treatment of endothelial
cells showed reduced tube formation possibly through
inhibition of proliferation [4, 14, 70–79]. In this study,
we describe a reduction of tube formation, as measured
by the number of nodes, junctions and branches,
dependent on intact Activin A signaling. Additionally,
we observed that fibroblast-derived overexpression of
Activin A downregulates vascular endothelial growth
factor expression, one of the key components of tumor
angiogenesis (data not shown). Previous research iden-
tified that the majority of endothelial cells expresses
ActRII/IIB and are therefore able to respond to Activin
A ligand binding [66, 72, 78–83]. However, as we use
conditioned media from fibroblast-secreted Activin A
organotypic cultures, the effects we measured on tube
formation may be indirect. In vitro co-culture studies of
fibroblasts and endothelial cells in the presence of ESCC
cells have shown that tumor cell-secreted TGFβ can acti-
vate fibroblasts resulting in VEGF secretion and increased
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formation of endothelial network formation [84]. A
number of pro-angiogenic factors were downregulated
when we performed angiokine arrays (data not shown),
which may be under the regulation of Activin A. Add-
itionally, Activin A has been found to regulate several
secreted factors, such as IL-8, VEGF, GnRH, and PTGS2
[85–87]. Therefore, it can be difficult to conclude that
Activin A overexpression alone is responsible for all of the
observed effects in our experiments, particularly since
contradictory evidence has been previously observed [34].
However, our study investigates a long-term stable overex-
pression of Activin A in a three-dimensional context, ra-
ther than the utilization of recombinant Activin A for in
vitro treatments. Therefore, in this study, we are able to
investigate the paracrine signaling effects due to epithelial-
fibroblast crosstalk.
In this paper, we showed that Activin A plays a neces-
sary role in controlling mechanisms of esophageal squa-
mous cell carcinoma invasion and, most likely, tumor
progression. Activin A signaling from the stroma, e.g.
fibroblasts, regulates expression of extracellular matrix
proteins and thereby the signaling pathways involved in
cell invasion. It has been found the expression of Activin
type I receptors (ActRI and ACVRIB) and type II
receptor (ActRII) mediates Activin A effects in collagen
gel contraction using human lung fibroblasts [88]. In
pancreatic stellate cells, autocrine Activin signaling
induces activation and collagen secretion [89]. We
observed the loss of podoplanin and fibronectin in
response to overexpression of Activin A, but also αSMA-
and podoplanin-double positive fibroblasts in most of the
invasive cultures. In the context of fibrosis, which is
characterized by the presence of myofibroblasts, Activin A
has been shown to regulate myofibroblast differentiation
mediated by integrin α11β1, a collagen receptor on
fibroblasts [90].
Interestingly, we believe that Activin A, when unable
to bind and signal through ACVRIB, is then free to
associate with other receptor complexes, such as BMPR2
or BMPR1/ALK2, and propagate a signal [91, 92]. This
data highlights, for the first time, the importance of
maintaining an intact Activin A signaling pathway to
control esophageal squamous cell carcinoma invasion.
Previous literature has shown that Activin A can bind
with low affinity and transduce a signal through subse-
quent TGFβ family receptors, of particular note the
BMP receptors [93]. Substantial research has demon-
strated that induction of the BMP pathway can result in
production of collagens, commonly leading to bone
formation [94, 95]. In fact, Activin A has been reported
to regulate ECM mineralization, as well as enhance
BMP-induced formation of bone and collagen [96, 97].
This may be a mechanism to control ECM formation
aside of ACVRIB-dependent Activin A signaling.
Conclusion
In conclusion, we have demonstrated that in a dysplastic
esophageal squamous microenvironment, Activin A works
to inhibit cell invasion into the stroma, however, when the
pathway becomes dysregulated, such as through the
downregulation of ACVRIB, cells are rendered unre-
sponsive. Dysregulation of the Activin A pathway may
be a way in which cancer cells can adapt to circumvent
inhibitory environmental factors.
Additional files
Additional file 1: Figure S1. “Epithelial and stromal markers do not
vary between ESCC patient samples, by stage”; control staining and
analysis of TMA data. A comparison of ESCC patient samples, using
immunofluorescence staining on a prepared microarray, showed that
epithelial keratin 14 (K14) (a), stromal vimentin (b), the extracellular
matrix protein collagen (c), and monocyte marker CD68 (d) expression
did not significantly differ between stage and esophageal squamous
cell carcinoma (SCC) versus lymph node metastasis (LN Met).
(TIF 4401 kb)
Additional file 2: Figure S2. “Overexpression of Activin A, validated by
ELISA, was persistent and did not affect fibroblast contractility”; validation
of assays by ELISA and cell contractility assay. (a) Overexpression of
Activin A was validated following each retrovirus transduction. Levels
of secreted Activin A protein, measured in conditioned media, were
significantly higher in Act A compared to parent and empty vector
control, ECdnT, TE-2, and TE-11 cells in 2D monolayer. Overexpression
of Activin A was validated throughout the 17-day organotypic culture
with ECdnT (b), TE-2 (c), and TE-11 (d). Fibro-ActA had sustained increased
expression of Activin A during this time period. (e) Parent, empty, and
Fibro-ActA had comparable ability to contract collagen, indicating that
overexpression of Activin A alone did not hinder the fibroblasts ability to
contract the extracellular matrix. 3-butanedione monoxime (BDM) was used
as an assay control. (f) Quantification (percent) of fibroblast matrix contraction
from (e). (One-way ANOVA, *p<0.05). (TIF 4375 kb)
Additional file 3: Figure S3. “Activin A overexpression reduced
proliferation of TE-2, but not ECdnT and TE-11 cells”; quantification of
Ki67 from ECdnT, TE-2, and TE-11 organotypic cultures in Figs. 2, 4, and 5.
Proliferation of (a) ECdnT, (b) TE-2, and (c) TE-11 esophageal cells, as
measured by nuclear Ki67 immunofluorescence staining, in three-
dimensional organotypic cultures with parent, empty, and Fibro-ActA.
(One-way ANOVA, *p<0.05). (TIF 4401 kb)
Additional file 4: Figure S4. “Endothelial tube formation assays
following treatment with recombinant proteins and the chemical
inhibitor, A83-01”; endothelial tube formation assays and quantification
following treatment. (a) Brightfield images of HMEC-1 endothelial tube
formation assays treated with recombinant protein (TGFb, Activin A, or
Follistatin) or the chemical inhibitor A83-01. (b) Treatment of HMEC-1
cells with Activin A, Follistatin, or A83-01, but not TGFb, increased the
number of formed endothelial extremities. (c-d) Compared to media
control, treatment with recombinant protein (TGFb, Activin A, Follistatin)
or A83-01 increased the number of endothelial tube nodes and junctions,
respectively. (e) Treatment of HMEC-1 cells with Activin A, Follistatin,
or A83-01, but not TGFb, increased the number of formed endothelial
extremities. (One-way ANOVA, *p<0.05; scale bar = 200 µm).
(TIF 4401 kb)
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